Findings

What do systematic reviews say?

43 questions · 43 findings · 8 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 16.3%GRADE not reported 4 · 9.3%Very low 11 · 25.6%Low 14 · 32.6%Moderate 6 · 14%High 1 · 2.3%

Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Serious adverse events (52 weeks) · Patients with quiescent ulcerative colitis

It is very uncertain whether probiotics changes serious adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).

1 finding from 1 review

Probiotics for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.19 [0.41, 3.46]
1 study · 327 participants
Very low

Azathioprine or 6‐mercaptopurine vs 5‐ASA or Sulfasalzine

Withdrawals due to adverse events · Patients with active Crohn's disease

Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with 5‐ASA or Sulfasalzine (low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.98 [0.38, 2.54]
2 studies · 156 participants
Low

Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Withdrawals due to adverse events · Patients with quiescent ulcerative colitis

It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).

1 finding from 1 review

Probiotics for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.02 [0.46, 2.25]
1 study · 222 participants
Very low